News & Updates
Filter by Specialty:
Navitoclax–ruxolitinib combo doubles spleen response rates in myelofibrosis
In untreated myelofibrosis, using navitoclax in combination with ruxolitinib appears to result in a twofold increase in the number of patients experiencing spleen volume shrinkage, regardless of prognosis, according to updated data from the phase III TRANSFORM-1 trial.
Navitoclax–ruxolitinib combo doubles spleen response rates in myelofibrosis
17 Aug 2024
Multiple factors influence risks of cirrhosis, HCC in veterans with MAFLD
The incidence of cirrhosis and hepatocellular carcinoma (HCC) among veterans differs according to demographic and clinical characteristics, with the lowest rate seen among Asians, reports a study.
Multiple factors influence risks of cirrhosis, HCC in veterans with MAFLD
17 Aug 2024
AI improves physician accuracy in identifying prostate cancer extent
Use of artificial intelligence (AI)-assisted cancer contours helps minimize underestimation of the extent of prostate cancer, thereby improving the physician’s ability in terms of contouring accuracy and negative margin rate, a study has shown.
AI improves physician accuracy in identifying prostate cancer extent
16 Aug 2024
![[Infographics] 1L lorlatinib achieves longest ever PFS in ALK+ NSCLC: 5-year data from the CROWN trial](https://prdmspst.blob.core.windows.net/images/articles/hk-pfi-842mo00-1ba26a3f-ad9e-4a40-a539-5b8900e99a1a-square.png)
[Infographics] 1L lorlatinib achieves longest ever PFS in ALK+ NSCLC: 5-year data from the CROWN trial
American Society of Clinical Oncology (ASCO) 2024: 5-year data from the international, randomized, open-label phase III CROWN trial comparing lorlatinib vs crizotinib in treatment-naïve patients with advanced ALK+ non-small-cell lung cancer (NSCLC) demonstrate unprecedented progression-free survival (PFS) with lorlatinib.
